LEVODOPA PHARMACODYNAMICS

被引：0
|
作者：
CONTIN, M
RIVA, R
MARTINELLI, P
CORTELLI, P
ALBANI, F
BARUZZI, A
机构：
来源：
NEUROLOGY | 1994年 / 44卷 / 02期
关键词：
D O I：
10.1212/WNL.44.2.366
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [31] EFFECT OF LONG-TERM THERAPY ON THE PHARMACODYNAMICS OF LEVODOPA - RELATION TO ON-OFF PHENOMENON
    NUTT, JG
    WOODWARD, WR
    CARTER, JH
    GANCHER, ST
    ARCHIVES OF NEUROLOGY, 1992, 49 (11) : 1123 - 1130
  • [32] Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments
    Nicholas H. G. Holford
    Phylinda L. S. Chan
    John G. Nutt
    Karl Kieburtz
    Ira Shoulson
    Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33 : 281 - 311
  • [33] Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations
    Baas, H
    Harder, S
    Bürklin, F
    Demisch, L
    Fischer, PA
    CLINICAL NEUROPHARMACOLOGY, 1998, 21 (02) : 86 - 92
  • [34] Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Nyholm, D.
    Bjornsson, M.
    Karlsson, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 608 - 608
  • [35] Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients - Discussion - Dr. Nutt
    Obeso
    Nutt
    Reichmann
    Olanow
    Lieberman
    Koller
    Fahn
    Gordin
    Waters
    Dingemanse
    Reichmann
    Brooks
    Guttman
    Hauser
    NEUROLOGY, 2000, 55 (11) : S38 - S41
  • [36] Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics
    Baas, H
    Harder, S
    Demisch, L
    Burklin, F
    Stecker, K
    Fischer, PA
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (46): : 367 - 379
  • [37] EFFECT OF PERIPHERAL CATECHOL-O-METHYLTRANSFERASE INHIBITION ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF LEVODOPA IN PARKINSONIAN-PATIENTS
    NUTT, JG
    WOODWARD, WR
    BECKNER, RM
    STONE, CK
    BERGGREN, K
    CARTER, JH
    GANCHER, ST
    HAMMERSTAD, JP
    GORDIN, A
    NEUROLOGY, 1994, 44 (05) : 913 - 919
  • [38] Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease
    Zappia, M
    Colao, R
    Montesanti, R
    Rizzo, M
    Aguglia, U
    Gambardella, A
    Oliveri, RL
    Quattrone, A
    ANNALS OF NEUROLOGY, 1997, 42 (02) : 245 - 248
  • [39] Effects of a dopamine agonist on pharmacodynamics of levodopa in Parkinson's disease: A double-blind placebo controlled crossover study
    Brodsky, M. A.
    Park, B. S.
    Nutt, J. G.
    MOVEMENT DISORDERS, 2008, 23 (01) : S319 - S319
  • [40] Pharmacokinetic-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Bjornsson, M.
    Karlsson, M.
    MOVEMENT DISORDERS, 2021, 36 : S162 - S162
12345